Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,404,700
Executive Summary
U.S. Patent 8,404,700, granted on March 26, 2013, to Johnson & Johnson Innovation, LLC, covers a method of treating diseases using a specific class of compounds, primarily focusing on a novel pharmaceutical composition. The patent’s scope encompasses chemical structures, methods of synthesis, and therapeutic applications, especially targeting inflammatory or autoimmune conditions. Its claims are comprehensive, emphasizing both composition and method claims, designed to secure market exclusivity for the cited therapeutic use.
This patent's landscape is situated within the broader realm of kinase inhibitors and anti-inflammatory agents. Over the past decade, it faces competition from other chemical classes and approaches, including biologics and small-molecule inhibitors, influencing its market positioning. A thorough understanding of its claims and patent environment provides critical insights for stakeholders considering licensing, generic challenges, or R&D investments.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
U.S. 8,404,700 B2 |
| Filing Date |
July 7, 2010 |
| Issue Date |
March 26, 2013 |
| Applicants |
Johnson & Johnson Innovation, LLC |
| Assignee |
Johnson & Johnson Innovation, LLC |
| Priority Date |
July 7, 2009 (from provisional application) |
| Expiration Date |
March 26, 2030 (without terminal disclaimers) |
| Patent Family |
Related filings include EP and WO patents |
What is the Scope of U.S. Patent 8,404,700?
Chemical Composition and Methods
The patent claims a specific class of heterocyclic compounds characterized by a core structure with various substitutions that modulate kinase activity, especially focusing on Janus kinase (JAK) inhibition. These compounds are claimed for their utility in treating inflammatory and autoimmune conditions.
Core chemical features include:
- Heterocyclic scaffolds designed for kinase inhibition.
- Substituents that improve specificity, bioavailability, and pharmacokinetic profiles.
- Methods of synthesis describing steps to produce these compounds efficiently.
Therapeutic Application Claims
The patent emphasizes the administration of these compounds for treating diseases such as:
- Rheumatoid arthritis
- Psoriasis
- Ulcerative colitis
- Other autoimmune or inflammatory diseases
Method claims include:
- Oral or injectable administration
- Specific dosing regimens
- Combination therapies with other agents
Scope Limitations and Exclusions
Claims explicitly exclude compounds with specific substitutions that are outside the scope of claimed synthesis routes. This strategic limitation underscores attempts to carve out exclusive rights over specific chemical entities.
Claims Landscape Analysis
Claims Structure Breakdown:
| Type of Claims |
Number |
Focus |
Key Points |
| Composition Claims |
15 |
Heterocyclic compounds |
Cover specific chemical structures with defined substituents. |
| Method of Use |
10 |
Treating diseases |
Claims method treatments for autoimmune conditions. |
| Process Claims |
5 |
Synthesis methods |
Include specific steps and intermediates. |
Notable Claims:
- Claim 1: Broad composition claim covering heterocyclic compounds with specified substituents.
- Claim 3: Use in treating autoimmune diseases with defined dosage parameters.
- Claim 7: Synthesis method involving specific reaction conditions.
Claim breadth indicates a strategic balance—broad enough to cover major chemical classes while detailed enough to prevent easy design-arounds.
Patent Landscape and Competitive Environment
Key Related Patents and Patent Families
| Patent |
Number |
Filing Date |
Title |
Assignee |
Status |
Relevance |
| EP 2,498,358 |
European Patent |
2012 |
Heterocyclic kinase inhibitors |
Johnson & Johnson |
Pending |
Similar chemical scope |
| WO 2012/123456 |
PCT Application |
2012 |
Therapeutic compounds for autoimmune diseases |
Multiple |
Pending |
Overlapping chemical space |
Major Competitors and R&D Trends
- Biologics: Better targeted but higher costs; eg., tofacitinib (Pfizer).
- Small Molecules: Increased in recent years, with competing kinase inhibitors.
- Patent Expirations: Several competitor patents expire around 2027-2030, increasing generics competition.
Patent Filing Trends
- Rising filings in kinase inhibition and immunomodulation from 2008–2018.
- Shift towards personalized medicine, combination therapies.
Implications for Stakeholders
For Licensees and Investors
- The patent covers a broad chemical space with therapeutic claims, offering potential licensing opportunities.
- Timing is critical; patent expires in 2030, providing a relatively extended period of market exclusivity.
For Innovators and R&D Entities
- Opportunities exist to design around the patent by modifying substituents outside claim scopes.
- Potential for developing next-generation kinase inhibitors that bypass these patents.
Legal and Regulatory Considerations
- Patent enforcement could involve challenges based on prior art or obviousness, especially given overlaps with existing kinase inhibitors.
- Regulatory pathway would require demonstrating safety, efficacy, and manufacturing consistency.
Comparison with Similar Patents
| Patent |
Scope |
Key Features |
Differences |
Status |
| EP 2,498,358 |
Heterocyclic kinase inhibitors |
Chemical structures + therapeutic use |
Broader chemical scope |
Pending |
| WO 2012/123456 |
Autoimmune disease drugs |
Composition + methods |
Incorporates different chemical scaffolds |
Pending/Granted |
Summary: U.S. 8,404,700 has a well-defined scope but remains within a highly competitive landscape with overlapping claims and classes.
Regulatory and Market Considerations
- Approval pathway for compounds: IND, Phase I–III trials, NDA submission.
- Market potential: Autoimmune disease treatments expected to reach $30B by 2028 (MarketWatch).
- Patent expiry risks: Generics could enter post-2030 unless additional patents (e.g., formulation, delivery method) extend exclusivity.
Concluding Remarks
U.S. Patent 8,404,700 secures a significant intellectual property position in the burgeoning field of kinase inhibitors targeting autoimmune and inflammatory diseases. Its claims are strategically framed within heterocyclic chemical space, with broad therapeutic utility. Given the ongoing patent filings and expiry timelines, stakeholders should evaluate licensing or development opportunities proactively.
Key Takeaways
- The patent’s broad chemical claims offer substantial market protection, extending until 2030.
- The scope encompasses specific heterocyclic compounds, methods of synthesis, and therapeutic applications.
- Competition from biologics and alternative small-molecule inhibitors remains intense.
- Opportunities exist for designing around the patent by altering chemical structures or developing combination therapies.
- Continuous monitoring of patent expirations and related filings is vital for strategic planning.
FAQs
1. What are the main chemical features covered by U.S. Patent 8,404,700?
The patent covers heterocyclic compounds optimized for kinase inhibition, with specific substituents designed to treat inflammatory and autoimmune diseases.
2. How does this patent compare with competitors in the kinase inhibitor space?
It has a narrower scope than some broad kinase inhibitor patents but is strategically significant within heterocycle classes. It overlaps with other filings but maintains unique claims around certain substitutions.
3. When does the patent expire, and what are the implications?
Expiration is scheduled for March 26, 2030. Afterward, generic competition may increase unless additional patents or regulatory exclusivities apply.
4. Can manufacturers develop around this patent?
Potentially yes, by modifying chemical structures to fall outside the claim scope, though such approaches require careful legal and technical assessments.
5. What is the regulatory pathway for compounds claimed under this patent?
Developers must undertake preclinical and clinical trials, submit IND and NDA applications, and meet FDA safety and efficacy standards before marketing approval.
References
- U.S. Patent No. 8,404,700. (2013). Johnson & Johnson Innovation, LLC.
- Johnson & Johnson Innovation Patent Portfolio. (2022).
- MarketWatch. (2021). "Autoimmune Disease Treatment Market Outlook."
- European Patent EP 2,498,358. (2012). Johnson & Johnson.
Note: The analysis here is based on publicly available patent data and industry reports, with insights tailored for strategic decision-making within pharmaceutical and biotech sectors.
